Fig. 5: RARα-Nrf2 complex activation after combined treatment with DAC and ATRA.

Immunoprecipitation and immunoblotting indicated the formation of a RARα-Nrf2 complex in MDS-L and MOLM-13 cells treated with DAC, as a single agent or combined with ATRA. The expression level of HDAC1 binding to the complex was reduced after the combination treatment.